Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MLYCD | O95822 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14241836 | 0.80 | MEN1 (0.59) | TSHRMLYCDNAMPTKMT2AMEN1 | |
| SCHEMBL13855532 | 0.80 | TDP1 (0.50) | HTTKMT2AMEN1TDP1GAA | |
| SCHEMBL10104241 | 0.79 | KMT2A (0.48) | TSHRHTTHSD17B10KMT2AMEN1 | |
| SCHEMBL15468365 | 0.79 | TDP1 (0.49) | HTTKMT2AMEN1TDP1GAA | |
| SCHEMBL21472789 | 0.77 | KMT2A (0.39) | TSHRHTTHSD17B10KMT2AMEN1 | |
| SCHEMBL19425799 | 0.76 | TSHR (0.33) | TSHRHTTHSD17B10MLYCDNAMPT | |
| SCHEMBL22859846 | 0.76 | TSHR (0.41) | TSHRMLYCDNAMPTKMT2AMEN1 | |
| SCHEMBL15887524 | 0.76 | TSHR (0.49) | TSHRMLYCDNAMPTKMT2AMEN1 | |
| SCHEMBL19606789 | 0.76 | TSHR (0.41) | TSHRMLYCDNAMPTKMT2AMEN1 | |
| SCHEMBL10061720 | 0.76 | MAPK1 (0.54) | TSHRHSD17B10MLYCDNAMPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858349-B2 | Compositions and methods for the treatment of cancer | CELLIX BIO PRIVATE LIMITED (IN) | 2020-12-08 | — | — | US | disclosed |
| US-20190292171-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | CELLIX BIO PRIVATE LIMITED (IN) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292171-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | SI, HBG2, HBG1 | TSHR 3208/4885HTT 3856/4885HSD17B10 1921/4885 |
| US-10858349-B2 | Compositions and methods for the treatment of cancer | SI, HBG2, HBG1 | TSHR 3208/4885HTT 3856/4885HSD17B10 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.